<?xml version="1.0" encoding="UTF-8"?>
<p id="par0040">Recently, Y. Wang et al. reported randomized, double-blind, placebo-controlled trial in hospitalized adults with severe COVID-19 in China. Adverse effects such as constipation, hypoalbuminemia, hypokalemia, anemia, and thrombocytopenia as well as increased total bilirubin concentrations were reported in 66 % of patients who received RemdesivirÂ®. Serious adverse events reported in 18 %, and drug discontinued because of the adverse events [
 <xref rid="bib0080" ref-type="bibr">16</xref>].
</p>
